ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Dr. Safi Shahda on a Phase Ib Study Investigating BBI-608 for mPDAC

Safi Shahda, MD
Published Online: 7:23 PM, Wed March 9, 2016


Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study looking at a combination of BBI-608, gemcitabine, and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Shahda says so far, 8 patients from the study have been reported on in terms of efficacy and 18 patients have been reported on in terms of safety. He adds that the combination thus far appears to be tolerable with manageable toxicities.

Shahda says the toxicities associated with BBI-608 are generally gastrointestinal in nature, which involves abdominal cramping, nausea, and diarrhea. These toxicities are normally grades 1 and 2, and are manageable with supportive care. Shahda adds that BBI-608 does not have overlapping toxicities with either gemcitabine or nab-paclitaxel. 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.